Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

COVICI-SURV: COVID-19 Vaccination Around Immune Checkpoint Inhibitor Initiation and Survival in a Nationwide Cohort of Patients With Cancer

NCT07729241 is registered in ClinicalTrials.gov with Groupe Hospitalier Pitie-Salpetriere as lead sponsor.

NCT NCT07729241
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07729241 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
COVICI-SURV: COVID-19 Vaccination Around Immune Checkpoint Inhibitor Initiation and Survival in a Nationwide Cohort of Patients With Cancer
Lead sponsor
Groupe Hospitalier Pitie-Salpetriere
Phase
Observational
Overall status
Completed
Start date
December 28, 2020
Completion date
September 10, 2026
Enrollment
95,015 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

cancer, covid-19 vaccination, immune checkpoint inhibitors, survival